Ameriprise
TEVA icon

Ameriprise’s Teva Pharmaceuticals TEVA Stock Holding History

Ameriprise’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-37,100
Closed -$2.19M – 3937
2015
Q2 		$2.19M Buy
+37,100
New +$2.29M ﹤0.01% 2697

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Ameriprise's TEVA Position: Q2 2026 in Review

Ameriprise increased its Teva Pharmaceuticals (TEVA) stake by 599% in Q2 2026, buying an estimated $22.2M and bringing the position to 778,837 shares worth $26.4M. The position accounts for 0.01% of the portfolio, ranked #1328.

Ameriprise first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $163M in Q4 2015. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ameriprise held 778,837 shares of Teva Pharmaceuticals worth $26.4M as of Q2 2026.
  • Ameriprise bought 667,346 Teva Pharmaceuticals shares in Q2 2026, an estimated $22.2M.
  • Teva Pharmaceuticals made up 0.01% of Ameriprise's portfolio in Q2 2026, its #1328 holding.
  • Ameriprise first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Ameriprise's Teva Pharmaceuticals position peaked at $163M in Q4 2015.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.